Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA)

Slides:



Advertisements
Similar presentations
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European.
Advertisements

Pathways – Dr Duncan Fowler
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European.
Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors’ Expert Forum. Featured Article: Itamar Raz, M.D.,
Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.
Treatment Strategies for Diabetes and Obesity: Update 2013 Christopher Sorli, MD/PhD, FACE Chair, Department of Diabetes, Endocrinology and Metabolism.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University Sellami Mnif Houda.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Insulin Initiation With NovoMix30
Case Presentation – Assessment 3
NURS 785: Pharmacotheraputics for Nurse Prescribing Assignment 3: Case Presentation Student ID: Auckland University September 2014.
Copyright © 2015 by the American Osteopathic Association.
Achieving Optimal Glycaemic Control: Can Insulin Deliver?
Copyright © 2015 by the American Osteopathic Association.
Algorithm for the metabolic management of type 2 diabetes mellitus; reinforce lifestyle interventions at every visit and check hemoglobin A1c every 3 months.
Copyright © 2017 American Academy of Pediatrics.
Placebo Metformin ***p < vs placebo
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
SGLT2 Inhibitors in Phase 3 Trials
Modulation of the intensiveness of glucose lowering in type 2 diabetes
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Updates to Managing Diabetes in the Long-Term Care Setting
Sequential insulin strategies in type 2 diabetes.
Athena Philis-Tsimikas, MD  The American Journal of Medicine 
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Insulin Use in Primary Care: Practice Challenges
Disease Progression in Type 2 Diabetes
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.
Strategies for the Practical Management of Type 2 Diabetes
Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.
Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
2015 EASD In Review: CV Risk management in t2dm
(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).
Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.
Mechanisms of metformin in humans.
Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.
Current insulin dose (units/kg/day) during the DCCT/EDIC study by sex (black line for females) (A), DCCT intensive vs. conventional treatment group (black.
Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.
Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.
Effect of empagliflozin on efficacy parameters at week 18.
Glycemic control and body weight over 52 weeks.
Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.
RBP4 and glucose metabolism.
(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.
Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Distribution of daily frequency of BGM
Initiation and adjustment of insulin regimens.
Risk of mortality in patients with diabetes and ESRD
The ADA research program supports research across the broad spectrum of diabetes types and research topic areas (proportions of 2011 allocations in dollars).
Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.
Cumulative mean numbers of confirmed (plasma glucose ≤3
Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.
Presentation transcript:

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2015;38:140–149 Diabetologia 2015; /s Inzucchi SE, Bergenstal RB, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR

Figure 1. Modulation of the intensiveness of glucose lowering therapy in T2DM Diabetes Care 2015;38: ; Diabetologia 2015; /s

Figure 2. Anti-hyperglycemic therapy in T2DM: General recommendations Diabetes Care 2015;38: ; Diabetologia 2015; /s

Figure 2. Anti-hyperglycemic therapy in T2DM: General recommendations Diabetes Care 2015;38: ; Diabetologia 2015; /s

Figure 2. Anti-hyperglycemic therapy in T2DM: General recommendations Diabetes Care 2015;38: ; Diabetologia 2015; /s

Figure 3. Approach to starting & adjusting insulin in T2DM Diabetes Care 2015;38:140; Diabetologia 2015; /s